Skip to Content
s - Skip to Content
0 - Access key details
1 - Back to top
2 - Header search

Tag: Medicaid

Assessment of Washington State’s Medicaid Prescription Drug Management Performance and Policy Options

This report explores which prescription drug model is best suited for Washington’s Apple Health (Medicaid) program: the current carve-in prescription drug model, under which managed care organizations (MCOs) pay for members’ prescriptions, or a carve out model, where prescriptions are…

Optimizing Medicaid MCO Procurements

This edition focuses on Medicaid MCO procurements, an area where our company conducts vast project work. We describe a few actions states can take to get the most value out of their procurements. We also offer some thoughts regarding how…

Medicaid MCO NCQA Accreditation Tabulations: Rating Year 2022-2023

This 5 Slide Series edition provides our tabulations and analysis of NCQA’s Quality Ratings for Medicaid MCOs juxtaposed with the specialized accreditations NCQA has awarded to these health plans.

Medicaid MCO Quality Tabulations: NCQA Rating Year 2022-2023

This 5 Slide Series edition provides our tabulations and analysis of the NCQA Quality Ratings for Medicaid MCOs (Rating Year 2022-2023).

Medicaid MCO Innovations to Address the Opioid Epidemic

This edition provides excerpts of opioid-related questions that have appeared in Medicaid MCO procurements. These slides demonstrate some of the ways in which states are using their request for proposal (RFP) process to promote innovation and elevate the MCOs’ mechanisms…

Quantifying the Impact of State-Level Policy Changes on Opioid Prescription (and Unit) Volume ​

This edition looks at various state-level policy changes seeking to restrict inappropriate use of opioids, conducting a pre-versus-post comparison of prescription opioid usage related to the dates of these policy changes.

Trends in the Use of Prescription Opioids and MAT in the Medicaid Program  ​

This edition focuses on the trends in Medicaid prescription opioid and MAT use.  An example of our findings is that opioid prescriptions per Medicaid enrollee decreased 54% from 2013-2022.
Back to top